Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$132.13 - $177.45 $132,130 - $177,450
-1,000 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$32.0 - $47.43 $32,000 - $47,430
1,000 New
1,000 $42,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Sarissa Capital Management LP Portfolio

Follow Sarissa Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sarissa Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Sarissa Capital Management LP with notifications on news.